TWI265008B - Nutritional formulation comprising oligofructose and sialyllactose - Google Patents
Nutritional formulation comprising oligofructose and sialyllactose Download PDFInfo
- Publication number
- TWI265008B TWI265008B TW090103225A TW90103225A TWI265008B TW I265008 B TWI265008 B TW I265008B TW 090103225 A TW090103225 A TW 090103225A TW 90103225 A TW90103225 A TW 90103225A TW I265008 B TWI265008 B TW I265008B
- Authority
- TW
- Taiwan
- Prior art keywords
- sialyllactose
- oligofructose
- nutritional composition
- vitamin
- scope
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/1307—Milk products or derivatives; Fruit or vegetable juices; Sugars, sugar alcohols, sweeteners; Oligosaccharides; Organic acids or salts thereof or acidifying agents; Flavours, dyes or pigments; Inert or aerosol gases; Carbonation methods
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
- A23C9/203—Dietetic milk products not covered by groups A23C9/12 - A23C9/18 containing bifidus-active substances, e.g. lactulose; containing oligosaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/244—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from corms, tubers or roots, e.g. glucomannan
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Pediatric Medicine (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Dairy Products (AREA)
- Confectionery (AREA)
- Fodder In General (AREA)
Description
1265008 A7 B7 經濟部智慧財產局員工消費合作社印製 五、發明説明(1 ) 發明範圍 本發明係關於含前生命物質之營養處方,與使用此處方 於有益微生物之生長促進及致病有機體之抑制,特別是本 發明係關於含寡果糖(oligofructose)及唾液乳糖( sialyllactose)之營養處方。 發明背景 寡果糖爲首先於蔬菜中發現之天然寡糖族,如洋蔥及菊 苣植物的根部。寡果糖已知爲比菲德氏菌(Bifidobacteria )所需之一特殊物質(如Mitsuoka et al,「果糖-寡糖對 於腸內微生物之影響」,Die Nahrung· 3 , 5 - 6:427 - 436 (1 987 ))。 寡果糖可不經消化通過小腸而達大腸,在大腸中寡果糖 僅被有限的微生物所發酵,其包括大多數的比菲德氏菌, 即此等微生物有益於人類之健康(Bouhnik et al,「健康 人體中以短鏈果糖-寡糖施藥劑量增加糞比菲德氏菌」L Nutrition· 129:113-116) ° 例如寡果糖可被乳酸菌及比菲德氏菌有效利用。已知混 合如存在於人類結腸之細菌相,寡果糖會被比菲德氏菌優 先利用,存在於此”混合菌相”的其他細菌不是不生長就是 被抑制生長(如Gibson et al,「以寡果糖及胰島素選擇 性刺激人類結腸中之比菲德氏菌」Gastroenterol, 108:975 - 982 ( 1 995 ))。 此外,已知比菲德氏菌之代謝產物爲短鏈脂肪酸,其會 (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 1265008 A7 B7 五、發明説明(2 ) (請先閲讀背面之注意事項再填寫本頁) 產生消化道pH値下降之結果,此pH値的影響已被臨床觀 察到及記載成文獻於Mitsuoka et al,「果糖-寡糖對於腸 內微生物之影響」,Die Nahrung. 3, 5 -6:427- 436 ( 1987)。 唾液乳糖爲天然存在於人類乳汁及其他哺乳類乳汁中。 然而,人類乳汁中唾液乳糖的濃度顯著高於其他哺乳類。 兩種主要的唾液乳糖爲3’-唾液乳糖及6’-唾液乳糖,其 以1 : 3 ( 3’ : 6’)之相對比例存在於人類乳汁中。唾液乳 糖已知對於特定病原菌具有抗黏著之特性,例如唾液乳糖 被建議作爲抑制霍亂毒素(I do t a e t a 1,「藉由人類乳汁 部份及唾液乳糖抑制霍亂毒素」Biosci · Biotech· Bi ochem. 59:417-419)及幽門螺桿菌(Simon et al,「 經濟部智慧財產局員工消費合作社印製 藉由含唾液酸之寡糖抑制幽門螺桿菌附著於胃腸上皮細胞 」Infect ion and Immunity, 750 - 757,( 1 997 ) ) 〇 以其 已知之抗黏著特性,唾液乳糖已被用於治療許多醫療狀況 ,例如美國專利第55 1 4660及5753630號中所述之利用唾 液乳糖治療及抑制十二指腸潰瘍。美國專利第588307 9號 中敘述於哺乳類組織中利用唾液乳糖抑制幽門螺桿菌感染 症。 然而,利用兩種前生命物質之組合,特別是寡果糖及唾 液乳糖迄今尙未被欽述過。因此’由此可知此組合爲一*必 須品。 發明摘述 -4- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 1265008 A7 B7 五、發明説明(3 ) (請先閱讀背面之注意事項再填寫本頁) 本發明係關於營養組成物,其有效增加有益之比菲德氏 菌及抑制致病微生物附著於人類組織上。特別是本發明指 出包含寡果糖及唾液乳糖之營養組成物。本發明進一步指 出增加比菲德氏菌濃度及抑制病原菌附著於人類組織之方 法,其包含爲對腸施以含寡果糖及唾液乳糖之組成物。 圖示之簡單說明 圖1 :爲實例1所述之比菲德氏菌屬、芽孢梭菌屬( Clostridia)及類細菌屬(Bacteroides)之生長。 圖2 :爲實例2所述之乳汁比菲德氏菌(B. lactis)之 生長。 圖3 :爲實例3所述之芽孢梭菌屬、類細菌屬及乳汁比 菲德氏菌屬之生長。 發明之詳細說明 經濟部智慧財產局員工消費合作社印製 本組成物中有益之唾液乳糖包含3’-唾液乳糖及6’-唾液 乳糖之混合物,在此之唾液乳糖以使用3 ’ -唾液乳糖較佳 。本組成物中有益之唾液乳糖可根據任何已描述之方法製 備,如美國專利第 55759 1 6、57 1 4075、5278299、5374541 及5876980號。然而,這些被認可的習知技術中,任何已 知能用以製備唾液乳糖的合成及純化唾液乳糖之方法皆可 用於本發明。 本組成物之寡果糖成分能由天然存在的聚果糖(菊糖) 製備,其可於許多植物中發現,包括洋蔥、韭、小麥、菊 苣及洋薊,以菊苣最普遍被使用。寡果糖能藉由習知技術 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 1265008 A7 B7 五、發明説明(4 ) (請先閲讀背面之注意事項再填寫本頁) 自這些植物中足量的回收。自然存在的菊糖含有寡果糖及 果糖之高聚合物,菊糖能以其溶於熱水中加以分離,若有 需要,天然存在之寡果糖可以另溶於冷水中而分離。菊糖 可視情況將天然存在之寡果糖移除後,藉由水解轉換成爲 寡果糖,菊糖可藉由菊糖酵素改變爲低聚合物鏈的長度, 菊糖亦可藉由化學水解而降解爲低聚合物的鏈長。本組成 物之寡果糖成分亦可藉由合成而不藉由粹取步驟製備,寡 果糖可將蔗糖進行果糖轉換作用加以合成,其藉由 喃果 糖苷酶完成,其連接另外的果糖單體至蔗糖分子,以此方 式形成之寡果糖含有連接於終端葡萄糖單元之果糖單元。 如菊苣之植物的菊糖所獲得的寡果糖,其含有果糖鏈及具 有終端葡萄糖單元之果糖鏈,寡果糖藉由此種方法製備爲 商業上有利的。本發明之目的中寡果糖較佳的型態爲 Ra f t i 1 〇 s e®,其由 0 r a f t i S · A ., T i enen, Be 1 g i um · Again取得,其可了解任何已知的合成和/或分離寡果糖的 方法皆適合本發明。 經濟部智慧財產局員工消費合作社印製 本發明之營養組成物可由0.1g/L至10g/L之寡果糖及 6mg/L至10g/L之唾液乳糖組成,較佳的爲本組成物含有 〇.3g/L至6g/L之寡果糖及60mg/L至lg/L之唾液乳糖, 更佳的爲lg/L至3g/L之寡果糖及100mg/L至600mg/L之 唾液乳糖,最佳的爲約3g/L之寡果糖及約100mg/L之唾 液乳糖。 本發明者發現本營養處方中,寡果糖及唾液乳糖之組合 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 1265008 A7 B7 五、發明説明(6 ) 嬰兒處方能含有一種或多種脂質來源,其將被那些習知 技術所認可,嬰兒處方可進一步包含其他物質以具有有益 之效果,如核苷、免疫球蛋白、聚不飽和脂肪酸等。 根據本發明較佳的嬰兒處方如下所示: 經濟部智慧財產局員工消費合作社印製 成分 單位 每公 熱量 Kcal 67 2 蛋白質 g 15 乳漿:酪蛋白 60 : 40 脂肪 g 36 碳水化合物 g 72 寡果糖 g 3.0 唾液乳糖 mg 100 維生素A RE 750 混合天然胡蘿蔔素 IU 400 維生素D meg 10.6 維生素F mg 7.4 維生素K meg 67.0 維生素1(硫胺) meg 1000 維生素B2 (核黃素) meg 1500 維生素b6 (吡哆醇) meg 600 維生素B12 (氰鈷素) meg 2.0 菸鹼酸 meg 9.0 葉酸 meg 80 mi· In ·ϋι In - - ml I In n i I (請先閱讀背面之注意事項再填寫本頁) 訂 -線」 本紙張尺度適用中國國家標準( CNS ) A4規格(210X297公釐) 1265008 A7 B7 五、發明説明(7 ) 泛酸 meg 3000 生物素 meg 90 維生素c (抗壞血酸) mg 90 膽鹼 mg 100 肌醇 mg 33 鈣 Mg 460 磷 Mg 333 鎂 Mg 64 鐵 Mg 8.0 鋅 Mg 6.0 錳 meg 50 銅 meg 560 碘 meg 100 鈉 mg 160 鉀 mg 650 氯化物 mg 433 硒 meg 14 I-1! n n I n 111.^- ϋ 1111 n 11 n 線 (請先閲讀背面之注意事項再填寫本頁) 本發明進一步參考資料以下列實例敘述: 經濟部智慧財產局員工消費合作社印製 實例1 隔夜培養(PYG培養液’ 37°C ’無氧下)各生物體(芽 孢梭菌、類細菌或乳汁比菲德氏菌)之等量接種物( V 1.0),以固定攪拌下於各組培養液中(37°C,無氧下 )生長,無碳水化合物之各培養液(PYG )各別添加葡萄 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 1265008 A7 B7 五、發明説明(8 ) (請先聞讀背面之注意事項再填寫本頁) 糖(3.0g/L)、寡果糖(FOS3.0 g/L)、唾液乳糖(3’-或 6’-唾液乳糖 l〇〇ml/L)或寡果糖加唾液乳糖(各3.0g/L 及100ml/L),於各時間點(第1圖)於選擇性培養基上 (比菲德氏菌使用BIM-25培養基,芽孢梭菌及類細菌使 用威肯斯-查俊(Wilkens-chalgren)培養基)決定細菌 力價以檢測生長狀況,生長分析結果顯示於第1圖。 第1圖中,生長培養液中以3’-唾液乳糖替代葡萄糖, 在與葡萄糖比較下,結果芽孢梭菌及類細菌並無實質生長 。然而於寡果糖存在下,芽孢梭菌及嬰兒比菲德氏菌(B. infantis)之生長(類細菌除外)相似於葡萄糖存在下所 示。寡果糖加唾液乳糖之組合對於芽孢梭菌及類細菌之生 長並無效果,然而其對於嬰兒比菲德氏菌之生長有顯著效 果,尤其是在24小時時間點時,可知寡果糖加唾液乳糖 之組合對於嬰兒比菲德氏菌之生長有協同效果。 實例2 經濟部智慧財產局員工消費合作社印製 隔夜培養(PYG培養液,37 °C,無氧下)乳汁比菲德氏 菌之等量接種物(▽ 1 . 0 ),以固定攪拌下於各組培 養液中(37°C,無氧下)生長,無碳水化合物之各培養液 (PYG)分別添加葡萄糖(3.0g/L)、寡果糖(3.0g/L) 或寡果糖加唾液乳糖(3’-或以-唾液乳糖100ml/L),於 各時間點(第2圖)於選擇性培養基上(BIM-25培養基) 決定乳汁比菲德氏菌力價以檢測生長狀況,生長分析結果 顯示於第2圖。 -10- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) ~ 1265008 A7 B7 經濟部智慧財產局員工消費合作社印製 五、發明説明(9 ) 第2圖顯示乳汁比菲德氏菌於寡果糖存在下比葡萄糖存 在下較具顯著生長。然而在46小時時,於寡果糖及3’-或 6’ -唾液乳糖之組合存在下,乳汁比菲德氏菌之生長被顯著 地增強。 實例3 比菲德氏菌代謝副產品爲短鏈脂肪酸,在其存在下會降 低腸之pH値。 第3圖顯示芽孢梭菌、類細菌或乳汁比菲德氏菌於不同 時間培養後之分析。隔夜培養(PYG培養液,37°C,無氧 下)各生物體(芽孢梭菌、類細菌或乳汁比菲德氏菌)之 等量接種物(A__ ▽ 1 . 0 ),以固定攪拌下於各組培養液 中(37 °C,無氧下)生長,無碳水化合物之各培養液( PYG)如上述被添加,培養液之pH値於各時間點檢測,pH 値分析結果顯示於第3圖。 第3圖顯示於葡萄糖存在下,三種結腸細菌皆會降低pH 値。僅唾液乳糖存在下,亦皆會降低pH値,此一致的微 生物生長不佳可見於僅唾液乳糖存在下。於寡果糖存在下 pH値會降低,但芽孢梭菌及嬰兒比菲德氏菌之各培養液中 的pH値比葡萄糖存在下降低較小範圍,但類細菌培養液 中的pH値則與葡萄糖存在下之變化相似。於本發明寡果 糖及唾液乳糖之組合存在下,pH値比葡萄糖存在下降低較 大範圍。 然而,此pH値降低作用少於葡萄糖(芽孢梭菌)或相 -11- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) ----^--_-----艮-------訂------線h (請先閲讀背面之注意事項再填寫本頁) 1265008 A7 B7 Λ- 五、發明説明(10) 似於葡萄糖存在下之pH値變化(類細菌及乳汁比菲德氏 菌),當寡果糖於超過時間時,比菲德氏菌培養液中僅顯 示少量pH値降低,此一觀察現象特別引起興趣,有唾液 乳糖存在者比較僅有寡果糖之嬰兒比菲德氏菌培養液,其 戲劇性地降低了 pH値,因此,寡果糖及唾液乳糖之加成 效果存在。 本發明在不違反其精神及必要特質下可被具體化爲其之 特殊形式,因此上述說明書所指之發明範圍外,其參考資 料也應構成附加之申請專利範圍。 ----:--;-----Μ-------訂------線^- (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 -12 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐)
Claims (1)
1265008
六、申請專利範圍公告哀 第90 1 03225號「含寡果糖及唾 利案 (92年7月修正) 六申請專利範圍 1. 一種含寡果糖及唾液乳糖之營養組成物,其包含0 . 1 克/公升至10克/公升之寡果糖及6毫克/公升至10 克/公升之唾液乳糖,其中唾液乳糖爲3 ’ -唾液乳糖及 6’-唾液乳糖之混合物。 2. 如申請專利範圍第1項之營養組成物,其中唾液乳糖 爲3’-唾液乳糖。 3. 如申請專利範圍第丨項之營養組成物,其中唾液乳糖 爲6’-唾液乳糖。 4. 如申請專利範圍第1項之營養組成物,其中包含〇 . 3 克/公升至6克/公升之寡果糖及60毫克/公升至1克 /公升之·唾液乳糖。 5·如申請專利範圍第4項之營養組成物,其中包含1克 /公升至3克/公升之寡果糖及100毫克/公升至600 毫克/公升之唾液乳糖。 6·如申請專利範圍第5項之營養組成物,包含1 . 5克/ 公升之寡果糖及1 〇〇毫克/公升之唾液乳糖。 7. 如申請專利範圍第1項之營養組成物,其中該組成物 爲液體形式。 8. 如申請專利範圍第1項之營養組成物,其中該組成物 爲粉末形式。 9.如申請專利範圍第〗項之營養組成物,其中進一步包 含至少一種之維生素A、維生素D、維生素E及複合 維生素B 〇 1〇·如申請專利範圍第1項之營養組成物,其中更包含至 少一種之錦、鎂、鈉、鉀、磷、銅、鋅、碘、硒及鐵 〇 11·如申請專利範圍第丨項之營養組成物,其可爲嬰兒處 方、追蹤處方、幼兒處方、牛奶酵母乳、果汁、水果 基礎飮料、糖果、口香糖或菱形錠劑之形式。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50600900A | 2000-02-17 | 2000-02-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
TWI265008B true TWI265008B (en) | 2006-11-01 |
Family
ID=24012783
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW090103225A TWI265008B (en) | 2000-02-17 | 2001-02-15 | Nutritional formulation comprising oligofructose and sialyllactose |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1255449B2 (zh) |
JP (1) | JP2003522784A (zh) |
CN (1) | CN1229115C (zh) |
AR (1) | AR027450A1 (zh) |
AT (1) | ATE357854T1 (zh) |
AU (1) | AU2001238285A1 (zh) |
BR (1) | BRPI0108478B8 (zh) |
CA (1) | CA2400737C (zh) |
DE (1) | DE60127533D1 (zh) |
MX (1) | MXPA02008016A (zh) |
PT (1) | PT1255449E (zh) |
TW (1) | TWI265008B (zh) |
WO (1) | WO2001060346A2 (zh) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1243273A1 (en) * | 2001-03-22 | 2002-09-25 | Societe Des Produits Nestle S.A. | Composition comprising a prebiotic for decreasing infammatory process and abnormal activation of non-specific immune parameters |
PL375071A1 (en) * | 2002-10-11 | 2005-11-14 | Wyeth | Nutritional formulations containing synbiotic substances |
US7867541B2 (en) | 2003-04-14 | 2011-01-11 | Mead Johnson Nutrition Company | Compositions and methods of formulation for enteral formulas containing sialic acid |
US7951410B2 (en) | 2003-04-14 | 2011-05-31 | Mead Johnson Nutrition Company | Enteral compositions containing caseinoglycomacropeptide having an enhanced concentration of sialic acid |
DK1638418T3 (da) | 2003-06-23 | 2012-09-17 | Nestec Sa | Aminosyretilsætning til et sundt mikrobiota-økosystem |
US20050287247A1 (en) * | 2003-09-18 | 2005-12-29 | Sorensen Esben S | Infant formula |
WO2006012536A2 (en) | 2004-07-22 | 2006-02-02 | Ritter Andrew J | Methods and compositions for treating lactose intolerance |
US7973021B2 (en) | 2005-09-22 | 2011-07-05 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Immunomodulating agent in gut |
JP2009514511A (ja) * | 2005-11-04 | 2009-04-09 | アルラ フーズ アンバ | 天然のシアリルラクトースを濃縮した、乳製品由来の濃縮物及び、その調製方法 |
EP2258206B1 (en) | 2008-03-27 | 2012-05-16 | Morinaga Milk Industry Co., Ltd. | Acidic lactic acid bacterium beverage, and method for production of acidic lactic acid bacterium beverage |
KR101116864B1 (ko) * | 2008-08-01 | 2012-02-29 | 주식회사 베네비오 | 고지혈증, 지방간 또는 비만의 예방 또는 치료용 조성물 |
CA2752800C (en) | 2009-02-24 | 2017-12-05 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
NL2004200C2 (en) * | 2010-02-05 | 2011-08-08 | Friesland Brands Bv | Use of sialyl oligosaccharides in weight management. |
NL2004201C2 (en) | 2010-02-05 | 2011-08-08 | Friesland Brands Bv | Use of sialyl oligosaccharides to modulate the immune system. |
WO2011136647A1 (en) * | 2010-04-27 | 2011-11-03 | N.V. Nutricia | Use of 6'-sialyl lactose in infant and toddler nutrition |
WO2011136636A1 (en) * | 2010-04-27 | 2011-11-03 | N.V. Nutricia | Use of 6'-sialyl lactose in infant nutrition |
EP3202406A1 (en) | 2010-04-28 | 2017-08-09 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
CA2822664C (en) | 2010-12-31 | 2021-07-20 | Abbott Laboratories | Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof |
BR112013016914A2 (pt) * | 2010-12-31 | 2019-09-24 | Abbott Lab | combinação simbiótica de probióticos e oligossacarídeos do leite humano para promover o crescimento de microbiota benéfica |
SG191393A1 (en) | 2010-12-31 | 2013-08-30 | Abbott Lab | Neutral human milk oligosaccharides to promote growth of beneficial bacteria |
CA2822495C (en) | 2010-12-31 | 2020-12-22 | Abbott Laboratories | Methods of using human milk oligosaccharides for improving airway respiratory health |
DK2658549T3 (da) | 2010-12-31 | 2020-06-29 | Abbott Lab | Fremgangsmåder til reduktion af incidensen af oxidativt stress under anvendelse af humane mælkeoligosaccharider, vitamin c og anti-inflammatoriske midler |
EP2658547A1 (en) | 2010-12-31 | 2013-11-06 | Abbott Laboratories | Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides |
CA2822490C (en) | 2010-12-31 | 2020-03-31 | Abbott Laboratories | Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection |
EP3338784B1 (en) | 2010-12-31 | 2020-07-22 | Abbott Laboratories | Human milk oligosaccharides for modulating inflammation |
ES2527200T5 (es) | 2011-02-10 | 2022-12-29 | Nestle Sa | Modulación del crecimiento de las bífidobacterias mediante una combinación de oligosacáridos de la leche humana |
JP2014516589A (ja) | 2011-06-20 | 2014-07-17 | エイチ.ジェイ.ハインツ カンパニー | プロバイオティック組成物及び方法(probioticcompositionandmethods) |
EP2750523A1 (en) | 2011-08-29 | 2014-07-09 | Abbott Laboratories | Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract |
NL2007931C2 (en) | 2011-12-07 | 2013-06-10 | Friesland Brands Bv | Methods for providing sialylated oligosaccharides and products obtainable thereby. |
MX2017002155A (es) | 2014-08-18 | 2017-05-01 | Nestec Sa | Prebioticos para reducir el riesgo de obesidad mas tarde en la vida. |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5953834B2 (ja) * | 1982-05-19 | 1984-12-27 | 明治製菓株式会社 | ビフイズス菌増殖促進物質 |
MX9304638A (es) * | 1992-07-31 | 1994-05-31 | Neose Pharm Inc | Composicion para tratar e inhibir las ulceras gastricas y duodenales. |
WO1994018986A1 (en) * | 1993-02-26 | 1994-09-01 | Jan Staffan Normark | Use of oligosaccharide glycosides as inhibitors of bacterial adherence |
JPH07258093A (ja) * | 1994-03-23 | 1995-10-09 | Morinaga Milk Ind Co Ltd | 神経成長因子様剤 |
JP3501415B2 (ja) * | 1994-03-30 | 2004-03-02 | 雪印乳業株式会社 | ビフィズス菌および乳酸菌増殖促進剤 |
CN1129524A (zh) * | 1994-09-09 | 1996-08-28 | 哈尔滨松花江第二乳品厂 | 婴幼儿阶段奶粉 |
US5849324A (en) * | 1995-07-10 | 1998-12-15 | Abbott Laboratories | Use of indigestible oligosaccharides to reduce the incidence of otitis media in humans |
US5827526A (en) † | 1995-07-11 | 1998-10-27 | Abbott Laboratories | Use of indigestible oligosaccharides to prevent gastrointestinal infections and reduce duration of diarrhea in humans |
DE19701382A1 (de) * | 1997-01-16 | 1998-07-23 | Nutricia Nv | Kohlenhydratmischung |
MXPA00012399A (es) * | 1998-06-10 | 2003-07-14 | Albert B Crum | Complememnto nutricional profilactico y terapeutico para la creacion y mantenimiento de microflora intestinal protectora de la salud y mejoramiento del sistema inmunologico. |
EP1104998A1 (en) * | 1998-08-21 | 2001-06-13 | Advanced Nutricional Foods Pty. Limited | Composition |
-
2001
- 2001-02-15 PT PT01910704T patent/PT1255449E/pt unknown
- 2001-02-15 DE DE60127533T patent/DE60127533D1/de not_active Expired - Lifetime
- 2001-02-15 BR BRPI0108478A patent/BRPI0108478B8/pt not_active IP Right Cessation
- 2001-02-15 CA CA2400737A patent/CA2400737C/en not_active Expired - Fee Related
- 2001-02-15 EP EP01910704.4A patent/EP1255449B2/en not_active Expired - Lifetime
- 2001-02-15 WO PCT/US2001/004794 patent/WO2001060346A2/en active IP Right Grant
- 2001-02-15 CN CNB01805191XA patent/CN1229115C/zh not_active Expired - Lifetime
- 2001-02-15 AU AU2001238285A patent/AU2001238285A1/en not_active Abandoned
- 2001-02-15 JP JP2001559444A patent/JP2003522784A/ja not_active Ceased
- 2001-02-15 AT AT01910704T patent/ATE357854T1/de not_active IP Right Cessation
- 2001-02-15 MX MXPA02008016A patent/MXPA02008016A/es active IP Right Grant
- 2001-02-15 TW TW090103225A patent/TWI265008B/zh not_active IP Right Cessation
- 2001-02-16 AR ARP010100718A patent/AR027450A1/es active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
WO2001060346A2 (en) | 2001-08-23 |
CA2400737A1 (en) | 2001-08-23 |
EP1255449B2 (en) | 2016-06-08 |
EP1255449B1 (en) | 2007-03-28 |
PT1255449E (pt) | 2007-08-24 |
MXPA02008016A (es) | 2002-11-29 |
AR027450A1 (es) | 2003-03-26 |
CA2400737C (en) | 2010-12-14 |
BR0108478A (pt) | 2003-04-22 |
CN1406111A (zh) | 2003-03-26 |
ATE357854T1 (de) | 2007-04-15 |
BRPI0108478B8 (pt) | 2021-05-25 |
AU2001238285A1 (en) | 2001-08-27 |
DE60127533D1 (de) | 2007-05-10 |
BRPI0108478B1 (pt) | 2017-05-30 |
WO2001060346A3 (en) | 2002-01-17 |
JP2003522784A (ja) | 2003-07-29 |
CN1229115C (zh) | 2005-11-30 |
EP1255449A2 (en) | 2002-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI265008B (en) | Nutritional formulation comprising oligofructose and sialyllactose | |
US6630452B2 (en) | Nutritional formulation containing prebiotic substances | |
JP4008974B2 (ja) | ビフィズス菌増殖促進組成物及びその用途 | |
CN1731938B (zh) | 益生元组合物 | |
JP4148535B2 (ja) | ラクト−n−ネオテトラオースを含有する栄養配合物 | |
US20040072794A1 (en) | Nutritional formulations containing synbiotic substances | |
BRPI0408911B1 (pt) | composição de galactooligossacarídeos e a preparação da mesma | |
WO2007140621A1 (en) | Probiotic compositions and uses thereof | |
WO2007140622A1 (en) | Dairy-derived probiotic compositions and uses thereof | |
Aimutis | Lactose cariogenicity with an emphasis on childhood dental caries | |
CN104642870A (zh) | 一种益生元组合物 | |
CN111227261A (zh) | 一种益生元组合物及其应用 | |
CN109315769A (zh) | 一种用于改善人体肠内环境的组合物及其制备方法 | |
CN109561723A (zh) | 用于预防、治疗非轮状病毒相关性腹泻或降低其严重程度的包含低聚糖和任选地乳双歧杆菌的混合物的营养组合物和婴儿配方食品 | |
JP6163619B1 (ja) | 腸内細菌叢のバランスを改善するための組成物及び方法 | |
US9826766B2 (en) | Use of polysaccharides for the intestinal well-being of nursing infants and/or infants | |
CN103070332A (zh) | 抗致龋菌的糖组合物 | |
CN108719752A (zh) | 一种富含营养成分的功能性面粉 | |
Mountzouris | Nutritional strategies targeting the beneficial modulation of the intestinal microflora with relevance to food safety: The role of probiotics and prebiotics | |
KR20230139410A (ko) | 발효 및 섭취를 위한 프로바이오틱스 제조방법 | |
CN117615661A (zh) | 长双歧杆菌过渡型微生物的用途 | |
Ayyub et al. | International Journal of Research in Pharmacology & Pharmacotherapeutics | |
Akdevelioğlu | Prebiyotikler Nedir, Ne Değildir. | |
JP2004137194A (ja) | 便通改善組成物 | |
Paseephol | Characterisation of PrebioticCompoundsfrom Plant Sources and Food Industry Wastes: Inulin from Jerusalem Artichoke and Lactulose from Milk Concentration Permeate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |